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The aminoglycoside antibiotics are invaluable therapeutic agents but can cause deafness and, 3 in some instances, balance disorders, largely due to the loss of hair cells from the inner ear (1, 4
2). Due to their broad spectrum and rapid bactericidal activity they are indicated as part of 5 empirical therapy for evident or suspected sepsis and other serious infections (3, 4). A major 6 use is in paediatrics, with ~80% of newborns admitted to neonatal intensive care units being 7 treated with aminoglycosides (5, 6). Their use is also increasing due to emerging multidrug-8 resistant pathogens, e.g., in the treatment of cystic fibrosis and tuberculosis (3, 7). The long-9 term daily administration of aminoglycosides required to manage these conditions results in a 10 high incidence of hearing loss, affecting the quality of life (8, 9) . 11
12
Hair cells have a mechanosensory hair bundle located at their apical surface and there is 13 evidence that the aminoglycosides, known to be permeant blockers of the mechano-electrical 14 transducer (MET) channels in the hair bundle, enter into hair cells via these large-15 conductance cation channels (10) (11) (12) (13) (14) . Once inside the hair cell, the aminoglycosides cause 16 increases in reactive free radicals and mitochondrial calcium concentration, leading to either 17 apoptosis or necrosis (1, 2, 15) . Whilst there are many points at which aminoglycoside-18 induced hair cell death could be prevented, blocking ototoxin entry into hair cells may be the 19 most effective strategy for protection (10, 16) . 20
21
Recent studies (16) (17) (18) (19) (20) (21) (22) (23) have shown that the lateral line system of zebrafish larvae is a 22 powerful model for discovering compounds that can protect sensory hair cells from the toxic 23 side effects of aminoglycoside antibiotics. At least 24 compounds have been described that 24 protect zebrafish lateral line hair cells, some of which (16, 20, 23) reduce or block the uptake 25 of Texas Red-conjugated gentamicin (GTTR) into the neuromast hair cells, whilst others (16, 26 19) block the uptake of both GTTR and FM1-43, a styryl dye that, like the aminoglycoside 27 antibiotics, acts as a permeant blocker of the hair-cell MET channel (24) . 28
29
Thus far, however, only four compounds discovered using zebrafish larvae have been 30
reported to protect hair cells of the mammalian inner ear from aminoglycoside antibiotics (21, 31 25, 26) . Two of these, tacrine and PROTO1, provide protection against aminoglycoside-32 induced hair-cell death in cultures of the utricular maculae of 3-6 week old mice (16, 21) . 33
Phenoxybenzamine (25) and berbamine have been shown, respectively, to cause partial and 34 4 full protection of OHCs in mouse cochlear cultures against aminoglycosides when used at a 1 low concentration. At slightly higher concentrations, however, both can cause OHC death 2 (25, 26). 3
4
We therefore sought to identify compounds that would protect mammalian OHCs from 5 aminoglycosides and not, either alone or in combination with the antibiotic, cause hair-cell 6 death or damage. As the hair-cell MET channel can be blocked by a variety of compounds 7 that also block other ion channels (27), a library of 160 known ion channel 8 agonists/antagonists (Tocriscreen Custom Collection Ion Channel Set) was screened on 9 zebrafish larvae using three different assays, seeking compounds that would either block FM 10 1-43FX dye loading, inhibit Texas Red-conjugated neomycin (TR-Neo) labelling, or prevent 11 neomycin-induced death of hair cells. Compounds effective in any of these three assays, 12
together with a small set of structurally similar compounds from the library, were then tested 13 in mouse cochlear cultures, screening for those that protect basal-coil mammalian OHCs 14 from gentamicin, a widely-used, clinically-relevant aminoglycoside antibiotic. 15
16
Results
17
Pre-selecting potential otoprotective compounds using zebrafish lateral line neuromasts 18
Three different screens of the Tocriscreen library were performed on zebrafish larvae at 4 19 dpf, a stage that ensures reliable loading of both FM1-43FX and Yo-Pro-1 into the hair cells 20 of lateral line neuromasts (28, 29) . In the first screen, the compounds were tested at a 21 concentration of 100 µM to determine if they would block or reduce the loading of 3 µM 22 FM1-43FX ( Figure 1A , B and D, Supplemental Figure 1A and B). In the second, compounds 23
were assessed at a concentration of 100 µM for their ability to reduce the entry of 25 µM TR-24
Neo into hair cells (Figure 1E, Supplemental Figure 1C and D) . In the third, the compounds 25 were tested at a concentration of 25 µM for their ability to protect hair cells pre-labelled with 26
Yo-Pro-1 from damage or death caused by exposure to 6.25 µM neomycin for 1 h ( Figure 1F , 27
Supplemental Figure 1E -H). Each screen was repeated on three independent occasions. 28
29
The FM 1-43FX screen identified 37 compounds that showed full or partial block of dye 30 loading ( Figure 1D ), the TR-Neo screen identified 53 compounds that showed complete 31 block or reduction of labelling ( Figure 1E ), and the neomycin-protection screen identified 43 32 compounds that either partially or fully protected hair cells ( Figure 1F ). One of the 33 5 compounds, suramin, provided a positive result in all three screens but is known to be 1 promiscuous in biological assays (30) and was therefore excluded from the results described 2 above and further consideration. One compound, 13228, consistently killed the larvae during 3 the neomycin-protection assay and it was therefore not possible to assess its potential 4 protective ability. Slowed circulation was also detected with this compound in the FM 1-5 43FX and TR-Neo assays. In total, 72 compounds were positive in one of the three assays on 6 at least one trial, and 19 of these were effective in all three, reducing FM 1-43FX loading, 7 TR-neomycin entry and neomycin-induced cell death. 8 9
Re-testing compounds from zebrafish screens in mouse cochlear cultures 10
The 72 compounds identified above, along with an additional six structurally similar 11 compounds from the library that were negative in all three zebrafish assays, were initially 12 tested in a single trial at a concentration of 50 µM in mouse cochlear cultures to see if they 13 would protect hair cells from exposure to 5 µM gentamicin for 48 h, a concentration of 14 gentamicin sufficient to kill hair cells in the basal third of the cochlea. Compounds that were 15 generally cytotoxic or failed to provide any evidence of protection at this step were not 16 pursued further. Those that improved basal-coil OHC survival in the presence of gentamicin 17
were subsequently re-tested on two or more independent occasions with the numbers of 18 individual cochleae used for each compound ranging from three to eleven. Using this 19 approach and the criteria described in the Supplemental Methods section, 12 protective 20 compounds (including one of the six selected on the basis of structural similarity to those that 21 were effective in the zebrafish) and one partially protective compound were identified ( Figure  22 2, Supplemental Table 1 , Supplemental Figure 2 ). When the concentration was reduced to 10 23 µM, three of the 13 compounds (13097, 13143 and 13170) were protective, six were partially 24 protective, and four provided no protection (Supplemental Table 1 
27
With eight of these 13 compounds that provided protection at 50 µM (13087, 13104, 13142, 28 13150, 13170, 13190, 13196 and 13228) , varying degrees of hair-bundle damage were 29 observed in the presence of gentamicin (Figure 2 ). To determine if any had adverse effects on 30 hair cells in the absence of gentamicin, they were tested alone at concentrations of 50 and 100 31 µM (Supplemental Figure 4, Figure 3 ). At 50 µM, five compounds (13087, 13150, 13170, 32 13196 and 13228) caused hair-bundle damage (Supplemental Figure 4B , G, I, K, and N). 33
When the concentration was increased to 100 µM, four compounds (13087, 13150, 13218 1 and 13228) were generally cytotoxic or caused loss of the sensory epithelium ( Figure 3B , G, 2 L and N), and a further four (13104, 13170, 13190 and 13196) caused hair-bundle damage 3 ( Figure 3I , J and K). Of the 13 compounds, only five (13097, 13142, 13143, 13154 and 4 13222) did not cause hair-cell death or hair-bundle damage at a concentration of 100 µM. 5
6
Two of the compounds, 13097 and 13143, those that did not cause hair-bundle damage when 7 tested alone at 100 µM and also provided protection against 5 µM gentamicin at a 8 concentration of 10 µM, were subsequently tested to determine the minimum concentration at 9 which they would protect against 5 µM gentamicin (Figure 4 and Supplemental Table 1 ).
10
Compound 13143 provided protection down to 1 µM (half-protecting concentration K = 840 11 nM) with a 95% confidence interval (CI) of 210-1480 nM, and compound 13097 was 12 effective at concentrations as low as 10 nM, with K = 4.9 nM (95% CI 2.2-7.7 nM). 13
14

Effects of otoprotective compounds on MET-channel currents in mouse OHCs 15
To determine if any of the 13 compounds that prevented gentamicin-induced hair-cell death 16 in cochlear cultures impede antibiotic entry via the MET-channel, we tested whether they 17 block MET currents in OHCs. Each compound was tested at a concentration of 50 µM at 18 membrane potentials ranging from -164 mV to +96 mV. Examples of MET currents recorded 19 before, during and after exposure to 50 µM of 13143 or 13222 are shown in Figure 5 , parts A 20 and B respectively. MET currents were unaffected during superfusion with 13143, but were 21 reduced in amplitude by 13222. This reduction in MET current amplitude caused by 13222 22
was observed at all potentials tested (-164 mV to +96 mV) and was strongest at moderately 23 hyperpolarized potentials. Current-voltage curves derived from the peak MET currents 24 recorded at all membrane potentials before, during and after compound exposure further 25 revealed the lack of interaction of 13143 with the channel ( Figure 5C ), and the voltage-26 dependence of the channel block by 13222 ( Figure 5D ). The MET currents and current-27 voltage curves also demonstrated that the currents fully recovered following 13222 exposure 28 indicating that the channel block was completely reversible. Of the 13 compounds tested, 29 seven had no effect on the MET current size across all membrane potentials indicating a lack 30 of interaction with the channel ( Figure 5E , Supplemental Table 1 ). Six of the 13 compounds 31 (13087, 13104, 13142, 13154, 13218 and 13222) interacted with the MET channel. All but 32 one of these (13087) provided a maximum block at moderately hyperpolarized membrane 33 potentials (e.g. at -44 mV for 13222) and a partial release of the block with both extreme 1 hyperpolarization and with depolarization ( Figure 5F , Supplemental whether any of the 13 compounds blocked the slow outward K + current (I K,neo ) that is 10 expressed by early postnatal mouse OHCs and activates at potentials positive to -50 mV (35).
11
OHCs were exposed to 30 µM of each compound and currents were elicited by applying a 12 series of hyperpolarizing and depolarizing voltage steps from a holding potential of -84 mV 13 ( Figure 6 ). Examples of currents recorded before, during and after application of three of the 14 compounds, the K v 7 blockers 13097 and 13143, and 13142, a compound that also blocked the 15 MET channel, are shown in Figure 6 (A, C and E), along with the activation curves derived 16 from the tail currents recorded before and during exposure ( Figure 6B , D and F). The average 17 reduction in the maximum conductance (G max ) of I K,neo caused by each compound and the 18 distribution of data are shown in Supplemental Table 2 and Figure 6G respectively. Of the 13 19 compounds tested, only two (13170 and 13196) had no effect on I K,neo at a concentration 30 20 µM ( Figure 6G , Supplemental Figure 8A , C, E, G), whilst a 5 significant decrease was seen in the presence of 5 µM gentamicin (z = 10.9, p < 0.001) 6
( Figure 8B , G). In cultures treated with 5 µM gentamicin in the presence of an additional 18 7 mM NaCl ( Figure 8D ), hair-cell loss was comparable to and not significantly different from 8 that observed with 5 µM gentamicin in normal medium (z = 0.12, p > 0.99) ( Figure 8B , G). 9
In cultures treated with 5 µM gentamicin in the presence an additional 18 mM KCl ( Figure  10 8F), there was a large and significant increase in hair-cell numbers relative to those observed 11 with 5 µM gentamicin in normal medium (z = 10.0, p < 0.001) ( Figure 8B , G), although 12 numbers were also significantly reduced relative to those observed in control medium without 13 gentamicin (z = 3.8, p = 0.001) ( Figure 8A , G Figure 8H -L). By contrast, perfusion with extracellular solution containing an additional 20 18 mM KCl caused a rapid depolarization of 15 +/-2.4 mV (+/-SEM; n = 10) of the OHCs 21 that reversed immediately upon washout ( Figure 8M ). 22
23
Zebrafish screen for compounds that protect against long-term gentamicin-induced damage 24
As three of the compounds that protect mouse cochlear hair cells against gentamicin did not 25 protect zebrafish hair cells from neomycin, and as there are known differences in the 26 mechanisms of action of gentamicin and neomycin in zebrafish hair cells (36), the 13 27 compounds proven to be effective in mouse cochlear cultures were retrospectively re-tested 28 in zebrafish using gentamicin as the ototoxic agent. At 100 µM, five of the compounds 29 (13143, 13150, 13170, 13190 and 13228) consistently caused loss of larval viability over the 30 five h time period of the experiment. Of the remaining eight compounds, all showed 31 protection against gentamicin damage ( Figure 9C -J). When the concentration of the 32 compounds was reduced to 50 µM, three (13143, 13150 and 13228) caused loss of viability, 33 six (13087, 13142, 13154, 13170, 13190 and 13196) showed partial protection (Supplemental 1 Figure 6C , F, G, H, I and J) and four (13097, 13104, 13218 and 13222) showed strong 2 protection (Supplemental Figure 8D , E, K, L). 3 4
Discussion 5 6
Using a combination of zebrafish lateral line organs and mouse cochlear cultures as screening 7 tools, we discovered 13 compounds that protect or provide partial protection of basal-coil 8 mouse OHCs from gentamicin-induced cell death ( Figure 10A ). In the zebrafish assays, two 9 out of the 13 compounds reduced FM1-43FX loading, five diminished TR-neomycin 10 labelling, and 10 provided protection from neomycin-induced cell death. Notably, however, 11 only one of the 19 compounds that was effective in all three zebrafish assays protected mouse 12
OHCs from gentamicin, and 10 of the 13 compounds that were successful in mouse cochlear 13 cultures would have been detected using the neomycin-protection assay alone. The added 14 value of the TR-neomycin labelling and FM1-43FX loading assays for future large-scale 15 screens is therefore questionable. A retrospective screen of the 13 compounds that protect 16 mouse cochlear hair cells in zebrafish using gentamicin rather than neomycin did not identify 17 all of the compounds, as a subset consistently caused a loss of larval viability over the longer 18 duration required for the assay (5 h for gentamicin as opposed to 1 h for neomycin).
19
Nonetheless, four of the five lead otoprotectants (see below) would have been identified had 20 the gentamicin assay been used for the primary selection. 21
22
Details of the 13 compounds that prevented or attenuated gentamicin-induced death of OHCs 23 in mouse cochlear cultures are shown in Figure 10B . All have reached different stages of 24 preclinical and clinical development, and the majority have physicochemical properties that 25 are ideal for oral absorption and potential passage through the blood-labyrinth barrier 26 (37). These include a MW of <450 daltons, a cLogP of <4, and a polar surface area (PSA) of 27 <80 Å 2 . Of the 13 compounds, four are known potassium channel blockers, four are 28 ionotropic glutamate receptor antagonists, and the other five belong to several different 29 classes of agonists or antagonists. The fourth physicochemical property shown in Figure 10 is 30 the pK a , a value that indicates the pH at which 50% of the molecules will be ionised. There is 31 a correlation between pK a and the ability of the compound to interact with the MET channel 32 and all the positively charged compounds (pK a > 8.0), with the exception of 13196 and 33 13228, were able to block the MET channel to varying degrees. The other compounds (pK a < 1 6.00) are in a neutral form at physiological pH and did not block the MET current. 2 3
By excluding all compounds that caused significant hair-bundle damage when tested alone at 4 100 µM and by selecting those that protect against 5 µM gentamicin at a concentration of 50 5 µM, five ion-channel inhibitors emerged as lead otoprotectants. These were 13142 ([±]-1-6
(1,2-diphenyl ethyl) piperidine) and 13222 (ifenprodil), NMDA receptor antagonists that also 7 block both the MET current and I K,neo in early postnatal mouse cochlear hair cells; two 8 inhibitors of K v 7 channels (38), 13097 (XE991) and 13143 (linopirdine) (32, 33, 39, 40) , both 9 of which block I K,neo but not the hair-cell MET current; and 13154, a selective antagonist of 10 the ATP-sensitive K + channel Kir6 that blocks both the hair-cell MET current and I K,neo .
11
Whilst all five compounds inhibit I K,neo , and although the results reveal K + -depolarization can 12 provide protection from gentamicin, none of them cause an immediate change in the resting 13 membrane potential of the OHCs, and none of them had an effect on the viability of the hair 14 cells in vitro over the course of 48 h. It is unlikely, therefore, that interactions between the 15 compounds and I K,neo determine their protective properties. The question therefore arises as to 16 how these five compounds protect OHCs in mouse cochlear cultures. 17
18
Previous studies have indicated aminoglycosides cause hair-cell death by activating NMDA 19 receptors and have shown that the NMDA modulators ifenprodil (13222), dizocilpine and 20 spermine limit aminoglycoside-induced hair-cell loss in both rats and guinea pigs in vivo (41-21 43). Whilst it has been unclear whether hair-cell death is due to a direct effect on hair cells or 22
indirectly via receptors present on the afferent fibres innervating the hair cells (44) The results identify five lead compounds that can be used to inform the development of drugs 16 for protecting sensory hair cells in the mammalian inner ear from the toxic side effects of the 17 aminoglycoside antibiotics. This more than doubles the number already identified as being 18 wholly or partially effective in mouse hair cells using a similar approach, i.e., preselection 19 using zebrafish lateral line neuromasts (16-23), proving the value of this strategy and 20 providing additional reagents that will help solve an ever increasing clinical issue. 21
22
Methods 23
24
Compound library 25 A Custom Collection Ion Channel Set of 160 biologically active compounds (ion channel 26 activators and inhibitors supplied pre-dissolved as 10 mM stock solutions in DMSO) was 27 obtained from Tocris. Molecules effective in one or more of the initial screens were 28 confirmed by testing new stocks from Tocris, HelloBio and Sigma-Aldrich. Purity was >95% 29 and compounds were used without further purification. Physicochemical properties were 30 calculated using MarvinSketch 16.8.15.0 by ChemAxon (https://www.chemaxon.com).
31
Chemical structures were drawn using ChemDraw Prime 15.0. 32
33
Zebrafish Assays 34
Zebrafish embryos were obtained from sibling crosses of adult nacre (mifta -/-) fish (51) either 1 housed at or obtained from the University of Sheffield. The nacre strain has reduced numbers 2 of pigmented melanophores and was used for the screens involving fluorescent compounds as 3 levels of autofluorescence are much lower and signal detection is thus improved. The 4 development of lateral line neuromasts and hair cells in this strain appears normal (for 5 examples, see Figure 1A and Supplemental Figure 1 ). Larvae at 4 dpf were dispensed into 6 96-well microtitre plates at a density of 3-4 per well. For the FM1-43 dye-loading assay 7 larvae were incubated in 100 µM compound (total volume of 100 µl) at room temperature for 8 10 mins, exposed to 3 µM FM1-43FX (Life Sciences F35355) for 1 min, washed and then 9 anaesthetised with 0.025% MS222. Wells containing larvae were imaged at 4x magnification 10 using the Phenosight imaging system (Ash Biotech) and larvae were scored for presence or 11 absence of fluorescently labelled neuromasts. If the larvae only had a small proportion of 12 neuromasts (e.g., only three terminal neuromasts or just the head neuromasts, see Figure 1A ) 13 labelled, the compound was described as a weak blocker. A compound was considered toxic 14 if there was loss of viability or the fish became fluorescent and neuromasts could not be 15 detected above background ( Figure 1C ). For the TR-Neomycin screen, larvae were incubated 16 in 100 µM compound and exposed to 25 µM TR-Neo for 90 seconds, washed and 17 anaesthetised. Entire larvae were imaged and scored for presence or absence of labelled 18 neuromasts with a 16x objective on a Zeiss IM-35 inverted microscope. The trunk 19 neuromasts (3-9) were assayed for presence or absence of fluorescence with a 40x objective.
20
A compound was designated as a weak blocker if fluorescence was only detected at 40x. The 21 neomycin protection and gentamicin screen was performed as described previously (26).
22
Briefly Yo-Pro-1 (Invitrogen Y3603) (29) pre-labelled larvae were incubated in 25 µM of 23 test compound with 6.25 µM of neomycin sulphate for 1 h or 50 or 100 µM of test compound 24 with 10 µM gentamicin sulphate (Sigma G3632) for 5 h .Plates were screened using a 16x 25 objective. Trunk neuromasts 3-9 were viewed and assessed as described in (26 The following were analysed using R 3.2.2 (54) with the 'lme4' package: 2
3
GTTR loading assay in mouse cochlear cultures 4
Texas Red-conjugated gentamicin loading was analysed using mixed-effects models, 5
assuming Normal error distributions. The compound applied was fitted as a categorical fixed 6 effect and the experimental design of hierarchical replication for each compound, grouped by 7 day, was fitted as random effects. Within this modelling framework, each compound was 8 compared to 1% DMSO control values using 2-tailed t-tests, assigning statistical significance 9 at p<0.05. 10
11
Mouse cochlear culture protection assay 12
The effects of gentamicin, NaCl and KCl on hair-cell survival were modelled using 13 generalized linear mixed effects models (GLMM), assuming Compounds are grouped according to biological activity. Compounds were given a score 39 where 0 = toxic, 1 = no block or no protection, 2 = weak block or partial protection, 3 = full 40 protection. Each screen was repeated 3 times so the pass threshold is >3 (at least one screen 41 with a score higher than one), Fail = 3 (three screens each with a score of one) and Toxic = 42 <3. Coloured dots identify compounds that protected hair cells in mouse cochlear cultures 43 from gentamicin. Green dots identify those that blocked the MET channel, and red dots those 1 that did not block the MET channel. All larvae were at 4 dpf. Scale bar = 1 mm. currents from OHCs in cultures prepared from P2 pups recorded before, during and after 6 exposure to (A) 50 µM 13143 (n = 12) and (B) 50 µM 13222 (n = 6). MET currents were 7 recorded at membrane potentials from -164 mV to +96 mV in response to a sinewave 8 stimulus. Current-voltage curves for the peak MET currents derived from the recordings 9
shown in panels A, B demonstrate the lack of interaction of 13143 with the channel (C) and 10 the voltage-dependence of block by 13222 (D). Fractional block of the MET currents at all 11 membrane potentials reveals that seven compounds, including 13143, do not interact with the 12 channel (E), whereas six compounds, including 13222, provide a voltage-dependent block 13 that is in most cases strongest at moderately hyperpolarized potentials (F). Error bars are 14 SEM. Number of independent tests are shown in the graph key after each compound number 15 in graphs (E) and (F). normal KCl levels (n = 10). Exposing the cells to the otoprotectant compounds 13097 (n = 24 10), 13142 (n = 5), 13143 (n = 11), 13154 (n = 7) and 13222 (n = 7) has no effect on the 25 resting membrane potential. Table  5 showing corresponding Venn numbers, identifier numbers, structure, commercial name and 6 known biological activity of the 13 compounds found to protect mouse OHCs from 7 gentamicin-induced damage at 50 µM. Molecular weight (MW), a measure of lipophilicity 8 (cLogP and cLogD), polar surface area (PSA) and pK a (pH at which the compound is 50% 9 ionised) for compounds are also included. Thick black lines separate compounds of differing 10 biological activity. Cultures were labelled with TRITC-phalloidin and images were acquired from the basal coil. 7
Asterisks identify compounds that damage hair bundles. Scale bar = 50 µm. and 100 µM of compound as indicated. Neuromasts were pre-labelled with 3 µM Yo-Pro-1. n 22 = 3 independent experiments with 3 or more fish per well. Table 2 : Potassium current activation curve data for the otoprotective 4 compounds 5
Average potentials at which the conductance is half activated (V 1/2 ) and voltage sensitivities 6 of activation (S) are shown for each of the 13 compounds found to provide protection in 7 mouse cochlear cultures. The deviation of V 1/2 from the control value is shown as a positive 8 value for depolarizing shifts and a negative value for hyperpolarizing shifts. Statistically 9 significant shifts were seen for five compounds (* p < 0.05; ** p < 0.01). The deviation of 10 voltage sensitivity (S) from the control value is shown as a positive value for reduced 11 sensitivity (i.e. greater value of S) and a negative value for increased sensitivity (smaller 12 value of S). Statistically significant changes in sensitivity were seen for four compounds (* p 13 < 0.05; ** p < 0.01). The maximum conductance (G max ) for each compound is shown as a 14 percentage of the control value. All compounds, except for 13170 and 13196, were found to 15 reduce G max by > 20 %. All values are mean ± SEM. Significance was shown by one sample 16 t-test (2-tailed testing) where * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 17
18
Supplementary Methods 19 20
Analysis of hair-cell survival (protection) in mouse cochlear cultures 21
Compounds that provided protection were each re-tested on 3-11 individual cochlear cultures.
22
Images of phalloidin-labelled hair cells were captured using a 40x objective (0.75 NA) on a 23 Zeiss Axioplan2 microscope from the mid-basal region, at a distance ~20% from the basal 1 (hook) end of the cochlea, using a Spot RT slider digital camera. If the cochlear epithelium 2 was not perfectly flat, images were obtained from multiple focal planes and merged using 3 Adobe Photoshop Creative Cloud (2017 Version) to ensure clear visibility of all cells present 4 in the region. Numbers of OHCs were counted in a 221 µm (1200 pixel) length of the organ 5 of Corti. The inclusion criterion for counting was the presence of a hair bundle, with 6 morphological changes to bundle structure being noted separately. The success or failure of a 7 compound was defined using a threshold. Cell counts from cultures grown in gentamicin 8 alone and gentamicin in the presence of the test compound were normalised to counts from 9 the negative control culture (no compound, no gentamicin, vehicle alone) within the same 10 experiment to generate a value for the percentage survival of basal-coil OHCs. A threshold 11 was produced by finding the mean percentage survival of all the gentamicin control coils for 12 a given drug at a given concentration and adding four standard deviations, the standard 13 deviation being generated from all the gentamicin-alone controls run throughout testing. This 14 method provides a stringent and relevant threshold for individual compounds at each 15 concentration tested that also takes into account variability of gentamicin performance across 16 experiments. 17
18
For analysis of hair-cell survival in cultures exposed to augmented levels of extracellular Na + 19 or K + , images were collected with a Jenoptik ProgRes Gryphax digital camera from the mid-20 basal coil of anti-myosin7a-labelled cultures using a 40x LDA Plan (0.55 NA) objective on a 21
Zeiss AXIO VertA1 inverted microscope. Numbers of surviving outer hair cells were counted 22 in three adjacent 100 µm 2 regions of interest from 3-6 cultures for each condition. For 23 statistical analysis see Statistics section. 24
25
Electrophysiology 26
Organotypic cultures on collagen-coated coverslips were transferred, after 1-2 days in 27 culture, to a microscope chamber which was continuously perfused with normal extracellular 28 solution containing (in mM): 135 NaCl, 5. were elicited by stimulating the OHC hair bundles using a fluid jet from a pipette (tip 10 diameter 8-10 µm) driven by a piezoelectric disc (12, 13) (12,13). Mechanical stimuli 11 (filtered at 1.0 kHz, 8-pole Bessel) were applied as 45 Hz sinusoids with driver voltage 12 amplitudes of ±40 V. Currents were acquired using pClamp (Molecular Devices) software 13 and stored on computer for off-line analysis. The test compounds were locally superfused 14 onto the OHCs at a concentration of 30 µM or 50 µM in a control solution containing (in 15 mM): 145 NaCl, 5.8 KCl, 1.3 CaCl 2 , 0.9 MgCl 2 , 0.7 NaH 2 PO 4 , 5.6 glucose, 10 HEPES-16 NaOH, 2 sodium pyruvate and BSA (0.5 mg.ml -1 ). The pH was adjusted to 7.48 (osmolality 17 ~305 mOsmol.kg -1 ). Negative pressure applied to the tip of the fluid jet pipette resulted in the 18 compound-containing solution being sucked into the pipette during superfusion. This 19 prevented any mixing and dilution of the compound with control solution during fluid jet 20 stimulation. MET currents were recorded before, during and after compound exposure at 21 membrane potentials ranging from -164 mV to +96 mV. 22
23
Basolateral currents were recorded before, during and after compound exposure at membrane 24 potentials ranging from -154 mV to + 46 mV from a holding potential of -84 mV (this value 25 includes a -4 mV correction for the liquid junction potential between extra-and intracellular 26 solutions). The reduction in size of the conductance contributed by I K,neo was determined 27 from the tail currents upon return of the membrane potential after the voltage steps to a 28 constant value away from the reversal potential V rev (-80 mV), at -44 mV. Tail current size 29 was plotted against membrane potential of the preceding voltage steps for the cells and the 30 data were fitted with a first-order Boltzmann function: 31
where I is the tail current, I max is the maximal tail current, V 1/2 is the half-activation potential, 1 V is the membrane potential of the preceding voltage steps and S is the voltage sensitivity of 2 activation. The maximum conductance of I K,neo was calculated from the tail currents as 3 ! !"# = ! !"# / ! − ! !"# . 4
In voltage-clamp recordings, membrane potentials were not adjusted for small errors (< 5 5 mV) due to residual series resistance (0.7 -1.5 MΩ). The resting membrane potential was 6 measured as the zero-current potential in voltage clamp mode and any changes subsequently 7 monitored in current-clamp mode before, during and after exposure to the test compounds. 
